Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Retained Earnings (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Retained Earnings readings, the most recent being -$2.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 99.93% year-over-year to -$2.1 million, compared with a TTM value of -$2.1 million through Dec 2025, up 99.93%, and an annual FY2025 reading of -$2.1 million, up 99.93% over the prior year.
  • Retained Earnings hit -$2.1 million in Q4 2025 for Apellis Pharmaceuticals, up from -$2.4 million in the prior quarter.
  • The five-year high for Retained Earnings was -$875000.0 in Q4 2022, with the low at -$3.2 billion in Q2 2025.
  • Median Retained Earnings over the past 5 years was -$1.7 billion (2021), compared with a mean of -$1.4 billion.
  • The sharpest move saw Retained Earnings tumbled 324184.34% in 2023, then soared 99.93% in 2025.
  • Year by year, Retained Earnings stood at -$2.1 million in 2021, then soared by 58.13% to -$875000.0 in 2022, then plummeted by 324184.34% to -$2.8 billion in 2023, then dropped by 6.97% to -$3.0 billion in 2024, then surged by 99.93% to -$2.1 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$2.1 million, -$2.4 million, and -$3.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.